The PreIND application has received a positive response from the US FDA at the end of last year. The FDA affirms Nanoray’s original combination product consisting of low-dose Transmission X-ray technology and photo-binding heavy atom drug for Auger Molecular Therapy (AMT). Regarding the contents of the PreIND file, Nanoray has already started the preparation and expects to finish IND delivery to be made in July. The milestone achieved will further the field of cancer treatment.
Positive response from US FDA, commercialization of our Auger cancer treatment has made significant progress._AMT